Dr David Rodriguez-Luna showed that achievement of systolic blood pressure target of <140 mmHg within 60min after hospital arrival was associated with lower rate of substantial hematoma expansion and early neurological deterioration, resulting in better function outcomes. This highlights that “time is brain” also holds true for ICH.
Prof. Juergen Beck, taught us that even though Mistie III was negative, selected patients do seem to benefit from minimal invasive surgery
Dr Catherine Lawrence took us from basic science to the clinical world by teaching us about models of haemorrhagic strokes.
Prof. David Seiffge concluded that a workup for an intracranial hemmorhage should include vessel imaging, brain imaging (preferably MRI) and of course other investigations depending on clinical hints. He outlined to consider iatrogenic CAA especially in young patients
Dr. Jean-Phillippe Désilles showed us endovascular treatment options of ruptured intracranial aneurysms and more specifically thought about the management of vasospasms, one of the most dreaded complications of aneurysmal subarachnoid hemorrhage.
Prof. Yinte Ruigrok demonstrated that screening for intracranial aneurysms is cost-effective in patients with at least 2 first-degree family members who suffered an aneurysmal subarachnoid hemorrhage or in patients with ADPKD (screening every 5 years). Screening in patients who have 1 first-degree family member with aneurysmal subarachnoid hemorrhage is possibly cost effective (and can be performed at the age of 40 an 55 years). Screening is not recommended in persons with a positive family history for unruptured aneuryms.